Niagen (nicotinamide riboside)
/ ChromaDex
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
1096
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
February 10, 2026
Effects of nicotinamide riboside supplementation during late gestation and lactation on sow performance, milk metabolome, and gut microbiome.
(PubMed, J Anim Sci Biotechnol)
- "Maternal supplementation of NR during late gestation and lactation increases sow performance and promotes gut NAD+ metabolic-associated microbiome remodeling. These findings propose maternal NR intervention as a novel strategy to enhance mammary lactogenesis and lactation metabolism in swine production, with potential applications for therapeutic strategies for lactation insufficiency."
Journal • NAMPT • TNFA
February 09, 2026
Hair growth enhancement via mitochondrial activation by Mito-activator complex.
(PubMed, Int J Cosmet Sci)
- "The approach of this study to promote hair growth through mitochondrial activation was successful. In addition, when applied to the human body beyond the in vitro level, a significant increase in hair growth was obtained without any side effects. In conclusion, this study suggested a promising candidate for hair loss treatment."
Journal • Alopecia • AMPK
February 09, 2026
NAD⁺ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence.
(PubMed, Ageing Res Rev)
- "Nicotinamide adenine dinucleotide (NAD⁺) declines with age, motivating "NAD⁺-boosting" strategies ranging from lifestyle interventions to supplementation with NAD⁺ precursors (e.g., nicotinamide riboside [NR], nicotinamide mononucleotide [NMN]) and, in some wellness settings, parenteral NAD⁺ administration...Overall, NAD⁺ augmentation shows clear biological activity, but clinical effectiveness for anti-aging or wellness outcomes remains inconclusive. Larger, well-designed randomized trials with longer follow-up and prespecified clinically meaningful endpoints are needed, particularly for parenteral approaches."
Journal • Preclinical • Review
January 29, 2026
SENIOR: Senolytics to Improve Osteoporosis Therapy
(clinicaltrials.gov)
- P2 | N=120 | Active, not recruiting | Sponsor: Odense University Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026
Enrollment closed • Trial completion date • Trial primary completion date • Osteoporosis • Rheumatology • TRAP
January 31, 2026
In vivo imaging of glutamate uncovers the neuroprotective effects of nicotinamide riboside on excitotoxicity in an Alzheimer's mouse model.
(PubMed, Alzheimers Res Ther)
- No abstract available
Journal • Preclinical • Alzheimer's Disease • CNS Disorders
January 28, 2026
The Use of Nutritional Interventions to Enhance Genomic Stability in Mice and Delay Aging.
(PubMed, Nutrients)
- " Our analysis covers a wide range of interventions with reported positive impacts on genomic stability, including modified diets (e.g., dietary restriction, probiotics, micronutrients, fatty acids, and hormones), NAD+ precursors (e.g., nicotinamide riboside), plant derivatives, and synthetic drugs...However, the observed overlap in mechanistic effects between treatments lends credibility to their potential efficacy. Ultimately, a deeper understanding of these mechanisms could pave the way for translating these findings into, e.g., combination treatments to promote healthy aging in humans."
Journal • Preclinical • Review
January 27, 2026
Nicotinamide Riboside in Ulcerative Colitis
(CCCongress 2026)
- No abstract available
Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
January 27, 2026
A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy
(clinicaltrials.gov)
- P2 | N=34 | Active, not recruiting | Sponsor: Ralitza Gavrilova | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Nov 2025 ➔ Nov 2026
Trial completion date • Trial primary completion date • Myositis
January 23, 2026
NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations.
(PubMed, JCI Insight)
- "Mechanistically, nicotinamide and nicotinamide riboside require the NAD+-dependent desuccinylase Sirt5 to enhance oxidative metabolism and nitrogen elimination through the urea cycle. Collectively, NAD+ supplementation activates Sirt5 to protect against damage to mitochondria and locomotor circuits caused by protein succinylation."
Journal • CNS Disorders • Genetic Disorders • Metabolic Disorders • SIRT5
January 23, 2026
Targeting CD38 for the prevention and treatment of Crohn’s disease-associated fibrosis
(ECCO-IBD 2026)
- "Human intestinal fibroblasts (CCD-18Co) will be stimulated with TNF or TGFβ, treated with an inhibitor of CD38 (78c) and the NAD precursor nicotinamide riboside, and assessed for fibrosis markers (COL1A1, ACTA2) and sirtuin activation...Anticipated impact This work is expected to demonstrate that CD38 inhibition reduces fibroblast activation and intestinal fibrosis in vitro and in vivo. Considering that drugs that target CD38 are already in use in other conditions, our findings may accelerate the development of antifibrotic therapies for CD resulting in reduced need for surgery and improved quality of life in CD patients."
IO biomarker • Crohn's disease • Immunology • Inflammatory Bowel Disease • ACTA2 • COL1A1 • TGFB1
January 22, 2026
Modulation of SIRT1/PPARγ pathways and tight junction proteins by nicotinamide riboside under chronic variable stress.
(PubMed, J Physiol Biochem)
- "• NR strengthened TJ/AJ proteins, supporting intestinal barrier integrity. • Findings support NR's therapeutic potential in stress-related metabolism."
Journal • CNS Disorders • Diabetes • Fibrosis • Genetic Disorders • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • FASN • PPARG • SIRT1
January 21, 2026
Nicotinamide Riboside in Ulcerative Colitis
(clinicaltrials.gov)
- P=N/A | N=40 | Recruiting | Sponsor: University of Pittsburgh | Trial completion date: Dec 2026 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026
Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
January 20, 2026
Metabolic Alterations Induced by a Seizure-Causing Sodium Channel Mutation and their Partial Normalization by Dietary α-Linolenic Acid in Drosophila.
(PubMed, Neurochem Res)
- "The paraShu mutation induced broad metabolic alterations, including enhanced glycolysis, reduced tricarboxylic acid cycle and pentose phosphate pathway intermediates, and depletion of nicotinamide riboside and nicotinic acid adenine dinucleotide, suggesting metabolic stress, mitochondrial dysfunction, and impaired redox balance...Dietary ALA partially normalized key metabolites, including succinate, 6-phosphogluconate, glycine, proline, and short-chain fatty acids, and increased N-methylnicotinamide, consistent with improved redox homeostasis and attenuated inflammation. These findings demonstrate that VGSC-driven hyperexcitability elicits coordinated metabolic and microbiota-related changes, and that ALA can mitigate these disturbances, highlighting testable metabolic targets for mechanism-based interventions in epilepsy."
Journal • CNS Disorders • Epilepsy • Inflammation • Metabolic Disorders • Solid Tumor
January 19, 2026
A multicenter, international, randomized, single-blind, placebo-controlled study of the efficacy and safety of inosine-nicotinamide-riboflavin-succinic acid in the acute period of traumatic brain injury in adults.
(PubMed, Front Neurol)
- P3 | "Further studies might be of research interest and clinical demand. ClinicalTrials.gov, identifier: NCT04631484; unique protocol ID: CTF-III-CCT-2019."
Clinical • Journal • CNS Disorders • Vascular Neurology
January 16, 2026
The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans.
(PubMed, Nat Metab)
- P=N/A | "To restore NAD+ levels, the main biosynthetic pathways have been targeted, with nicotinamide (Nam), nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) being the most prominent boosters...Overall, these results indicate a dual effect of NR and NMN and their microbially produced metabolite NA: a sustained increase in systemic NAD+ levels and a potent modulator of gut health. ClinicalTrials.gov identifier: NCT05517122 ."
Journal
January 16, 2026
Runx2 acetylation enhances pulmonary inflammation in chronic obstructive pulmonary disease through activating CDK8.
(PubMed, Respir Res)
- "These results indicated that Sirt3 depletion-induced Runx2 acetylation contributes to CDK8 activation and pulmonary inflammation in the progression of COPD."
Journal • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pneumonia • Pulmonary Disease • Respiratory Diseases • Targeted Protein Degradation • RUNX2 • SIRT3
January 16, 2026
NAD+-mediated SIRT1-LKB1-AMPK signaling drives lipid remodeling and meat quality differences between Daweishan miniature and Arbor Acres chicken breeds.
(PubMed, Front Vet Sci)
- "The concentrations of NAD+ and its key precursors, including nicotinamide (NAM), nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR), were higher (p < 0.05) in the M1 as compared to the A1 chicken breed...These results indicate that M1 chickens exhibit enhanced metabolic regulation and protein-rich muscle with distinct lipid remodeling, whereas A1 broilers favor rapid growth and fat accumulation. The study provides mechanistic insight into breed-specific differences in muscle metabolism and meat quality, highlighting NAD+ and its signaling axis as key regulators of lipid homeostasis in chicken breast muscle."
Journal • Metabolic Disorders • STK11
January 16, 2026
Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training
(clinicaltrials.gov)
- P=N/A | N=16 | Not yet recruiting | Sponsor: ZHANG Jiaqi
New trial
January 15, 2026
SUNRISE: Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants
(clinicaltrials.gov)
- P2/3 | N=40 | Not yet recruiting | Sponsor: University of California, Davis | Trial primary completion date: Dec 2026 ➔ Dec 2027
Trial primary completion date
January 13, 2026
Nicotinamide Riboside Mitigates Antiphospholipid Antibody-Induced Dysfunction in Human Trophoblast Cells.
(PubMed, Am J Reprod Immunol)
- "NR mitigated some, but not all, aPL-induced trophoblast dysfunction. This provides new insight into the role of antioxidant therapies on aPL-induced pregnancy complications, and a possible new avenue of managing obstetric APS to explore further."
Journal • Genetic Disorders • Hematological Disorders • Inflammation • Obstetrics
January 11, 2026
SIRT2 Mitigates Radiation-Induced Oral Mucositis by Promoting Homologous Recombination-Mediated DNA Double-Strand Break Repair in Epithelial Stem Cells.
(PubMed, Cancer Lett)
- "Importantly, SIRT2 activation-achieved via NAD+ supplementation in vitro or nicotinamide riboside (NR) in vivo-does not compromise the tumoricidal efficacy of IR in HNSCC models. These findings uncover a previously unrecognized protective role for SIRT2 in mucosal radiation injury and establish its activation as a promising, non-oncogenic therapeutic strategy to mitigate RIOM in patients receiving radiotherapy for head and neck cancer."
Journal • Head and Neck Cancer • Mucositis • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Stomatitis
January 10, 2026
Mitochondrial Health Through Nicotinamide Riboside and Berberine: Shared Pathways and Therapeutic Potential.
(PubMed, Int J Mol Sci)
- "By outlining overlapping and complementary mechanisms, we highlight NR and BBR as rational combinatorial strategies to restore mitochondrial resilience. This integrative perspective may guide the design of next-generation clinical trials and advance precision approaches in mitochondrial medicine."
Journal • Review • Cardiovascular • CNS Disorders • Metabolic Disorders • Ophthalmology
January 08, 2026
Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration.
(PubMed, J Peripher Nerv Syst)
- "At present oral NR supplementation, at the doses used in this study, cannot be recommended to prevent neuropathy or to improve nerve regeneration."
Clinical • Journal • Pain
January 07, 2026
NiRiD: Nicotinamide Riboside for Diabetic Neuropathy
(clinicaltrials.gov)
- P1/2 | N=10 | Terminated | Sponsor: University of Maryland, Baltimore | N=54 ➔ 10 | Suspended ➔ Terminated; Completed the pilot study and grant funding not obtained to continue to the main phase 2 study. The pilot study did not show a statistical significance in the primary or secondary outcome measures.
Enrollment change • Trial termination • Diabetic Neuropathy • Pain
January 06, 2026
Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats.
(PubMed, Hepatol Commun)
- "NR promotes liver regeneration after PVE in obese rats by enhancing NAD+-dependent metabolic pathways through the MCART1/ASB3 axis, offering a potential therapeutic strategy for obesity-associated liver dysfunction."
Journal • Preclinical • Addiction (Opioid and Alcohol) • Genetic Disorders • Hepatology • Inflammation • Liver Failure • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity
1 to 25
Of
1096
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44